Publicaciones en colaboración con investigadores/as de University of Bonn (12)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. Regulatory T Cell Inhibition by P60 Combined with Adenoviral AFP Transduced Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma

    Immunological Investigations, Vol. 52, Núm. 8, pp. 966-984

2017

  1. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

2014

  1. Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer

    OncoImmunology, Vol. 3, Núm. 1

  2. L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

    Experimental Neurology, Vol. 253, pp. 180-191

  3. L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus

    Neuropharmacology, Vol. 79, pp. 90-100

  4. Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4+ T cell tolerance

    Journal of Experimental Medicine, Vol. 211, Núm. 6, pp. 1153-1166

  5. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease

    Journal of Neuropathology and Experimental Neurology, Vol. 73, Núm. 5, pp. 414-424

2013

  1. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162

2011

  1. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

    Pharmacology and Therapeutics, Vol. 132, Núm. 3, pp. 280-299

  2. Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells

    Journal of Hepatology, Vol. 55, Núm. 4, pp. 828-837